Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]

Peer Review reports

Original Submission
3 Aug 2005	Submitted	Original manuscript
6 Oct 2005	Reviewed	Reviewer Report - Jennifer Cather
12 Oct 2005	Reviewed	Reviewer Report - Dan Pearce
2 Dec 2005	Author responded	Author comments - Eric Henninger
Resubmission - Version 2
2 Dec 2005	Submitted	Manuscript version 2
7 Dec 2005	Reviewed	Reviewer Report - Dan Pearce
9 Dec 2005	Author responded	Author comments - Eric Henninger
Resubmission - Version 3
9 Dec 2005	Submitted	Manuscript version 3
Publishing
16 Dec 2005	Editorially accepted
16 Dec 2005	Article published	10.1186/1471-5945-5-13

Back to article page